common glp 1 agonist Frontiers A clinician's perspective π GLP-1
Description
OG was funded by Brain research UK
Retatrutide is the potential new champion of efficacy, offering a distinct advantage in specific metabolic comorbidities, particularly liver health, due to its GIP GLP-1 Glucagon agonist structure
Parsons K., Montalvo M., Fischbach N., Taylor M., Alfaro S., and Lustberg M., The Impact and Safety of GLP1 Agents and Breast Cancer, Cancer Medicine 14, no
This in turn reduces the amount of insulin the body needs, ultimately resulting in reduced hyperglycemia and improved control of glucose levels
